Great Lakes NeuroTechnologies

Executive Summary

Great Lakes NeuroTechnologies (GLNT) is a privately held medical device company specializing in bioinstrumentation for physiological monitoring, with a primary focus on movement disorders such as Parkinson's disease. Founded in 2001 and based in Valley View, Ohio, GLNT has developed proprietary platforms including the Kinesia suite for objective, remote assessment of motor function and the BioRadio system for general physiological research and education. The company's wireless and web-based solutions enable continuous monitoring and telemedicine applications, positioning it to benefit from the growing demand for remote patient management and decentralized clinical trials. Despite limited public financial data, GLNT's long-standing presence and specialized product portfolio suggest a stable foothold in the neurology device market. GLNT's technology addresses a critical need in Parkinson's disease management, where quantitative, clinician-independent assessments can improve treatment decisions and clinical trial efficiency. The company has potential to expand its market through partnerships with pharmaceutical sponsors for drug development studies and integration with electronic health records. However, as a private entity, GLNT faces challenges in scaling commercial adoption and competing with larger medical device firms. Overall, the company offers niche value in neurodiagnostics with moderate growth prospects contingent on regulatory advancements and strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for next-generation Kinesia wearable sensor75% success
• Q2 2027Announcement of partnership with a top-20 pharmaceutical company for Parkinson's clinical trial monitoring50% success